Assuntos
Herpes Simples , Tonsilite , Adolescente , Herpes Simples/diagnóstico , Humanos , Simplexvirus , Tonsilite/diagnósticoRESUMO
Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available for the treatment of myelofibrosis. There are increasing reports of opportunistic infections associated with ruxolitinib therapy. We present a case of Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. Clinicians should consider the use of pneumocystis prophylaxis when using ruxolitinib.
Assuntos
Janus Quinases/antagonistas & inibidores , Pneumocystis carinii , Pneumonia por Pneumocystis/etiologia , Pirazóis/efeitos adversos , Idoso , Humanos , Hospedeiro Imunocomprometido , Masculino , Nitrilas , Pneumonia por Pneumocystis/prevenção & controle , Mielofibrose Primária/tratamento farmacológico , Pirazóis/uso terapêutico , PirimidinasRESUMO
The bowel-associated dermatosis-arthritis syndrome (BADAS), originally called the bowel bypass syndrome, and described after jejuno-ileal bypass, has subsequently been reported in association with inflammatory bowel disease and after gastric resection. BADAS has not been reported after biliopancreatic diversion (BPD). This case report describes a 47-year-old female who presented with recurrent skin rashes and arthralgia after a BPD, consistent with a clinical diagnosis of BADAS which was confirmed by skin biopsy. To date, she has been managed with cyclical courses of antibiotics without reversal of her surgery. This syndrome may be under-diagnosed and is a condition with which bariatric surgeons should be familiar.